科兴制药
(688136)
| 流通市值：46.01亿 | | | 总市值：46.01亿 |
| 流通股本：2.01亿 | | | 总股本：2.01亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 280,525,124.96 | 1,534,028,363.15 | 1,147,639,140.97 | 700,464,766.25 |
| 营业收入 | 280,525,124.96 | 1,534,028,363.15 | 1,147,639,140.97 | 700,464,766.25 |
| 二、营业总成本 | 300,163,833.04 | 1,479,489,096.16 | 1,070,420,698.89 | 653,551,426.35 |
| 营业成本 | 115,997,730.06 | 561,974,212.85 | 418,404,980.55 | 255,257,060.07 |
| 税金及附加 | 2,171,808.01 | 13,429,502.42 | 9,852,036.04 | 6,256,692.48 |
| 销售费用 | 112,836,122.69 | 574,296,480.79 | 420,667,831.17 | 254,953,408.24 |
| 管理费用 | 17,609,997.81 | 93,739,486.77 | 65,714,628.24 | 43,443,007.96 |
| 研发费用 | 34,066,000.91 | 199,553,069.24 | 132,621,448.46 | 81,662,554.29 |
| 财务费用 | 17,482,173.56 | 36,496,344.09 | 23,159,774.43 | 11,978,703.31 |
| 其中:利息费用 | 10,438,289.49 | 41,910,118.44 | 31,019,463.49 | 20,615,665.54 |
| 其中:利息收入 | 803,026.98 | 2,967,897.26 | 2,253,240.28 | 1,473,426.1 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -2,720,308.49 | 79,288,219.78 | 15,439,757.31 | 15,439,757.31 |
| 加:投资收益 | 2,232,766.63 | 29,823,017.46 | 27,187,204.78 | 23,176,579.52 |
| 资产处置收益 | 4,043 | 954,825.69 | 953,403.74 | -114,723.4 |
| 资产减值损失(新) | -3,926,021.5 | -2,342,216.31 | -2,050,530.99 | -978,079.61 |
| 信用减值损失(新) | -2,624,416.03 | -722,973.62 | -5,275,579.45 | -530,068.05 |
| 其他收益 | 981,554.1 | 6,570,527.58 | 4,201,064.44 | 2,304,815.88 |
| 四、营业利润 | -25,691,090.37 | 168,110,667.57 | 117,673,761.91 | 86,211,621.55 |
| 加:营业外收入 | 3,781.38 | 492,636.82 | 488,448.84 | 276,084.45 |
| 减:营业外支出 | 146,787.18 | 2,903,940.9 | 2,823,499.29 | 2,358,755.8 |
| 五、利润总额 | -25,834,096.17 | 165,699,363.49 | 115,338,711.46 | 84,128,950.2 |
| 减:所得税费用 | -7,280,257.7 | 12,955,104.41 | 6,236,575.12 | 5,166,478.14 |
| 六、净利润 | -18,553,838.47 | 152,744,259.08 | 109,102,136.34 | 78,962,472.06 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -18,553,838.47 | 152,744,259.08 | 109,102,136.34 | 78,962,472.06 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -17,936,565.06 | 155,567,752.57 | 111,262,991.17 | 80,344,468.24 |
| 少数股东损益 | -617,273.41 | -2,823,493.49 | -2,160,854.83 | -1,381,996.18 |
| 扣除非经常损益后的净利润 | -18,210,528.32 | 55,832,775.3 | 70,446,588.68 | 45,279,121.97 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.09 | 0.79 | 0.56 | 0.41 |
| (二)稀释每股收益 | -0.09 | 0.79 | 0.56 | 0.4 |
| 八、其他综合收益 | 263,706.13 | -180,713.14 | -80,087.15 | -25,544.5 |
| 归属于母公司股东的其他综合收益 | 263,706.13 | -180,713.14 | -80,087.15 | -25,544.5 |
| 九、综合收益总额 | -18,290,132.34 | 152,563,545.94 | 109,022,049.19 | 78,936,927.56 |
| 归属于母公司股东的综合收益总额 | -17,672,858.93 | 155,387,039.43 | 111,182,904.02 | 80,318,923.74 |
| 归属于少数股东的综合收益总额 | -617,273.41 | -2,823,493.49 | -2,160,854.83 | -1,381,996.18 |
| 公告日期 | 2026-04-29 | 2026-04-22 | 2025-10-30 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |